TABLE 1.
Baseline patient characteristics for alpha-1 blocker and 5ARI/PDE5 user cohorts in the OpenClaims data source. For each target (T) and comparator (C) cohort, we report the proportion of initiators satisfying selected base-line characteristics and the standardized mean difference (SMD) between the two cohorts before and after stratification. The smaller SMDs after propensity score adjustment demonstrates improved balance between the two cohorts.
| Open claims | ||||||
|---|---|---|---|---|---|---|
| Characterstics | Before stratification | After stratification | ||||
| N = 1,995,594 (T) and 366,734 (C) | ||||||
| T (%) | C (%) | SMD | T (%) | C (%) | SMD | |
| Age group | ||||||
| <25 | 0.1 | 0.1 | 0.00 | 0.1 | 0.1 | 0.00 |
| 25–29 | 0.1 | 0.1 | 0.00 | 0.1 | 0.1 | 0.00 |
| 30–34 | 0.1 | 0.1 | 0.00 | 0.1 | 0.1 | 0.00 |
| 35–39 | 0.2 | 0.2 | −0.01 | 0.2 | 0.2 | 0.00 |
| 40–44 | 0.4 | 0.4 | 0.01 | 0.4 | 0.4 | 0.01 |
| 45–49 | 1.2 | 0.8 | 0.04 | 1.2 | 1.0 | 0.01 |
| 50–54 | 3.1 | 1.8 | 0.08 | 2.9 | 2.7 | 0.01 |
| 55–59 | 7.0 | 4.1 | 0.13 | 6.6 | 6.2 | 0.02 |
| 60–64 | 12.2 | 8.1 | 0.14 | 11.6 | 11.3 | 0.01 |
| 65–69 | 17.4 | 13.9 | 0.10 | 16.8 | 16.9 | 0.00 |
| 70–74 | 19.2 | 19.2 | 0.00 | 19.2 | 19.1 | 0.00 |
| 75–79 | 16.7 | 19.2 | −0.07 | 17.1 | 17.4 | −0.01 |
| 80–84 | 17.1 | 24.1 | −0.18 | 18.1 | 18.7 | −0.02 |
| 85–89 | 5.3 | 7.8 | −0.10 | 5.7 | 5.8 | 0.00 |
| 90–94 | ||||||
| 95+ | ||||||
| Medical history: general | ||||||
| Chronic liver disease | 0.7 | 0.4 | 0.05 | 0.7 | 0.6 | 0.01 |
| Chronic obstructive lung disease | 7.0 | 5.4 | 0.07 | 6.8 | 6.7 | 0.00 |
| Dementia | 1.8 | 2.3 | −0.03 | 1.9 | 1.9 | 0.00 |
| Diabetes mellitus | 19.3 | 16.0 | 0.09 | 18.8 | 18.6 | 0.00 |
| Hyperlipidemia | 29.8 | 28.9 | 0.02 | 29.7 | 29.6 | 0.00 |
| Hypertensive disorder | 38.2 | 34.8 | 0.07 | 37.7 | 37.6 | 0.00 |
| Obesity | 3.9 | 2.7 | 0.07 | 3.7 | 3.5 | 0.01 |
| Renal impairment | 11.2 | 9.7 | 0.05 | 11.1 | 10.8 | 0.01 |
| Medical history: cardiovascular disease | ||||||
| Cerebrovascular disease | 3.3 | 3.2 | 0.05 | 11.1 | 10.8 | 0.01 |
| Ischemic heart disease | 4.0 | 3.6 | 0.03 | 4.0 | 4.0 | 0.00 |
| Medical history: neoplasms | ||||||
| Malignant neoplastic disease | 11.1 | 9.7 | 0.04 | 10.9 | 10.7 | 0.01 |
| Primary malignant neoplasm of prostate | 4.8 | 2.9 | 0.10 | 4.6 | 4.2 | 0.02 |
| Medication use | ||||||
| Antiinflammatory and antirheumatic products | 26.0 | 19.6 | 0.15 | 25.0 | 24.6 | 0.01 |
| Antineoplastic agents | 5.5 | 5.4 | 0.00 | 5.5 | 5.6 | 0.00 |
| Antithrombotic agents | 25.5 | 24.8 | 0.01 | 25.4 | 25.5 | 0.001 |
| Drugs used in diabetes | 26.1 | 21.5 | 0.11 | 25.5 | 25.4 | 0.00 |
| Immunosuppressants | 2.8 | 2.3 | 0.03 | 2.8 | 2.7 | 0.00 |